A rheumatologist manages osteoporosis from diagnosis through long-term treatment, handling everything from bone density testing and fracture risk assessment to choosing among a growing menu of medications, monitoring their safety, and deciding when to switch, pause, or sequence drugs. Rheumatologists are especially central to osteoporosis care when bone loss is driven by inflammatory diseases like rheumatoid arthritis or by the glucocorticoid medications used to treat them. The role goes well beyond writing a prescription and checking a scan once a year.
Assessing Fracture Risk Beyond a Single Scan
The first thing a rheumatologist does is figure out how fragile your bones actually are, and a bone density scan alone does not tell the whole story. Bone mineral density measured by DXA (dual-energy X-ray absorptiometry) remains the backbone of osteoporosis diagnosis, but a rheumatologist uses DXA data as one input among several. The WHO’s FRAX tool, for instance, combines DXA results with independent risk factors like rheumatoid arthritis and glucocorticoid use to estimate your ten-year probability of a major fracture.1PubMed Central. A review of the use of dual-energy X-ray absorptiometry (DXA) in rheumatology BMD alone is insufficient to fully capture fracture risk, and newer tools like the trabecular bone score (TBS) can complement density readings by giving a sense of bone microarchitecture quality.2PubMed. Enhanced bone quality assessment through trabecular bone score and bone mineral density in lumbar spine TBS is calculated from the same DXA image you already had, so it does not mean an extra test. Cross-sectional and longitudinal studies suggest TBS can independently predict fragility fractures and can be used to adjust FRAX probabilities.3PubMed Central. Trabecular Bone Score-An Emerging Tool in the Management of Osteoporosis
A rheumatologist also orders blood work to screen for secondary causes of bone loss. Baseline investigations typically include calcium, phosphate, alkaline phosphatase, vitamin D, parathyroid hormone, liver and kidney function tests, a full blood count, and thyroid-stimulating hormone.4PubMed Central. Secondary osteoporosis These tests can reveal hidden drivers of bone loss: an overactive thyroid, low vitamin D, kidney disease quietly leaching calcium, or an underlying blood disorder. Catching these matters because treating the underlying condition sometimes improves bone health on its own, and because certain osteoporosis drugs are safer or less safe depending on what else is going on in your body.
Bone turnover markers round out the picture. These are blood tests that measure how quickly bone is being broken down and rebuilt. Two markers in particular, CTX (a marker of bone resorption) and P1NP (a marker of bone formation), are endorsed as short-term monitoring tools to help clinicians assess how a patient is responding to therapy, often catching treatment failure or nonadherence earlier than a follow-up DXA scan would.5PubMed. Consensus Statement on the Use of Bone Turnover Markers for Short-Term Monitoring of Osteoporosis Treatment in the Asia-Pacific Region A rheumatologist can use either absolute values or the degree of change from baseline to judge whether a medication is doing its job.6PubMed Central. The Treatment and Monitoring of Osteoporosis using Bone Turnover Markers
Why Rheumatologists Are Particularly Suited to This Role
Osteoporosis is not exclusively a rheumatology problem. Endocrinologists, geriatricians, and primary care physicians all treat it. But rheumatologists occupy a unique position because two of the strongest risk factors for osteoporosis land squarely in their clinical territory: rheumatoid arthritis and chronic glucocorticoid use.
Rheumatoid arthritis drives bone loss through multiple pathways. The inflammatory process itself disrupts the normal balance between bone-building and bone-destroying cells, with cytokines and autoantibodies fueling resorption. Bone loss in RA can be focal, affecting joints directly, or generalized, leading to secondary osteoporosis throughout the skeleton.7PubMed Central. Pathomechanisms of bone loss in rheumatoid arthritis A rheumatologist treating RA is already managing the disease that causes the bone loss, which puts them in the best position to coordinate both sides of the problem.
Glucocorticoids, meanwhile, are prescribed across many rheumatic conditions: lupus, vasculitis, polymyalgia rheumatica, and RA itself. The American College of Rheumatology (ACR) strongly recommends that adults beginning or continuing more than three months of glucocorticoid treatment undergo fracture risk assessment as soon as possible, including a DXA with vertebral fracture assessment and FRAX scoring if over 40.8PubMed. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis The same guideline strongly recommends pharmacologic treatment for anyone at medium, high, or very high fracture risk on glucocorticoids. Because rheumatologists are the ones prescribing the steroids in the first place, the responsibility to protect bones falls naturally to them.
Choosing and Prescribing Osteoporosis Medications
One of the most consequential things a rheumatologist does is select the right drug at the right time. The osteoporosis medication landscape has expanded considerably, and the choice depends on your fracture risk level, kidney function, cardiovascular history, whether you can tolerate oral pills on an empty stomach, and how long you are likely to need treatment.
Bisphosphonates remain the most commonly prescribed first-line therapy for most patients. Oral options like alendronate and risedronate are taken weekly or monthly, while intravenous zoledronic acid is given once a year. Long-term data from extension trials show that women receiving alendronate for ten years had fewer clinical vertebral fractures than those switched to placebo after five years, and similar durability was seen with six annual infusions of zoledronic acid compared with stopping after three years.9PubMed Central. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Denosumab, an injectable given every six months, is a potent alternative. It works by blocking a signaling molecule involved in bone resorption. It can be an appropriate initial therapy in patients at high fracture risk, older patients who have difficulty with the dosing requirements of oral bisphosphonates, or those who are intolerant of or unresponsive to other therapies.10PubMed Central. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature It delivers sustained increases in bone mineral density and reduces vertebral and hip fractures for as long as it is administered. But denosumab comes with a significant management caveat discussed in the next section.
For patients at very high fracture risk, a rheumatologist may start with an anabolic (bone-building) agent rather than an antiresorptive. Teriparatide and abaloparatide are parathyroid hormone receptor agonists that tip the remodeling balance toward formation.11PubMed Central. Anabolic therapy for osteoporosis: update on efficacy and safety In postmenopausal women, teriparatide has been shown to reduce vertebral fractures by about 70% and non-vertebral fractures by about 45%.12PubMed Central. Anabolic treatment for osteoporosis: teriparatide These drugs are given as daily injections for up to two years.
Romosozumab is the newest addition, approved as a monthly injection for one year. It is the first medication that both increases bone formation and decreases bone resorption at the same time.13PubMed. Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis However, it carries a black box warning for cardiovascular risk and should be avoided in patients who have had a heart attack or stroke in the past year.14PubMed Central. Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives Clinical trials report an increased incidence of major adverse cardiovascular events, especially in patients with pre-existing cardiovascular conditions like chronic kidney disease, diabetes, or prior heart disease.15PubMed Central. Sclerostin and Cardiovascular Risk: Evaluating the Cardiovascular Safety of Romosozumab in Osteoporosis Treatment A rheumatologist’s job here is weighing that cardiovascular risk against the severity of the patient’s fracture risk, which requires the kind of nuanced clinical judgment that goes beyond a simple algorithm.
The ACR guideline for glucocorticoid-induced osteoporosis specifically recommends that the choice among bisphosphonates, denosumab, or parathyroid hormone analogs be made through shared decision-making with the patient. For those at high and very high fracture risk, anabolic agents are conditionally recommended as initial therapy.8PubMed. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Sequencing Treatments Over Time
Osteoporosis treatment is not a single prescription that stays the same forever. A rheumatologist plans a treatment sequence that unfolds over years, and the order in which drugs are used matters. An expanding body of trial evidence favors starting with an anabolic agent and then transitioning to an antiresorptive drug, rather than the reverse.16PubMed Central. Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis Therapy The logic is that anabolic therapy builds bone first, and then the antiresorptive locks in the gains.
This has been studied in patients with osteoporotic hip fractures, where short-term anabolic therapy followed by an antiresorptive significantly improved bone mineral density and normalized bone turnover markers.17PubMed Central. Short-term anabolic agent and sequential therapy to improve bone mineral density and bone turnover markers in patients with osteoporotic hip fractures Once patients reach more normal skeletal integrity through anabolic medication, antiresorptive agents help sustain those density and strength gains over the long haul.18Endocrine Practice. Anabolic Therapy and Optimal Treatment Sequences for Patients With Osteoporosis at High Risk for Fracture
A rheumatologist manages these transitions carefully. For instance, if a patient finishes a year of romosozumab or two years of teriparatide, the clinician needs to have an antiresorptive ready to go so the bone gains are not lost. This kind of forward planning is a core part of what a bone specialist does.
The Denosumab Discontinuation Problem
One area where a rheumatologist’s expertise is especially valuable is managing denosumab. Unlike bisphosphonates, which leave a residue in bone that continues to slow resorption for months or years after you stop taking them, denosumab’s effects reverse quickly once you miss a dose. When denosumab is discontinued, bone turnover surges above pre-treatment levels in what is called a rebound phenomenon. Most patients experience rapid bone loss, and a minority develop multiple vertebral fractures as a result.19PubMed Central. Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review Follow-on antiresorptive treatment after stopping denosumab is considered mandatory, though the optimal regimen is still being refined.10PubMed Central. Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
Recent evidence points to potent bisphosphonates as an effective bridge. A meta-analysis found that switching to a potent bisphosphonate after denosumab was associated with a 71% reduction in incident vertebral fractures compared to non-bisphosphonate alternatives, and a 92% reduction in the risk of multiple vertebral fractures.20PubMed Central. Potent bisphosphonate therapy for preventing fractures after denosumab discontinuation in osteoporosis A rheumatologist who prescribes denosumab has to plan for this exit strategy from the start, because a patient who simply stops showing up for injections faces real danger. This is the kind of ongoing management that distinguishes specialist care from a one-and-done prescription.
Bisphosphonate Drug Holidays
If you have been on a bisphosphonate for several years, your rheumatologist will eventually raise the question of a drug holiday. The rationale is straightforward: while long-term bisphosphonate use keeps fragility fractures at bay, it has been associated with two rare but serious side effects. Atypical femoral fractures, which are stress fractures in an unusual location on the thigh bone, and osteonecrosis of the jaw, which involves bone death in the jaw after dental procedures, both appear to increase in frequency with longer treatment duration.9PubMed Central. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Guidelines suggest considering a bisphosphonate holiday after three to five years, depending on the drug and the patient’s fracture risk.21PubMed Central. Bisphosphonate Drug Holidays: Evidence From Clinical Trials and Real-World Studies A large study using primary and secondary care data in England found that after three years of bisphosphonate use, the incidence of atypical femoral fractures was roughly 1.9 per 1,000 person-years, rising to about 2.5 per 1,000 person-years after five years. Osteonecrosis of the jaw was far rarer, at 0.07 per 1,000 person-years after three years. Reassuringly, interrupting or taking intermittent bisphosphonates after three or five years of continuous use was not associated with higher fragility fracture risk compared to staying on them.22PubMed Central. Fragility fracture, atypical femoral fracture, and osteonecrosis of jaw after bisphosphonate prescription for three and five years, based on primary and secondary care data in England: nested case-control and cohort studies
The rheumatologist’s role here is deciding who can safely take a holiday and who should stay on treatment. Someone with very high fracture risk or a history of vertebral fractures may not be a good candidate for a break, while someone whose risk has dropped to moderate after years of treatment might pause safely. During the holiday, the rheumatologist continues monitoring with DXA and sometimes bone turnover markers to catch any significant bone loss that would warrant restarting.
Dental Health and Jaw Safety
Patients often worry about jaw problems on osteoporosis medications, sometimes to the point of avoiding treatment entirely. A rheumatologist can put this risk into perspective. The evidence suggests that patients with osteoporosis treated with bisphosphonates carry an extremely low risk of medication-related osteonecrosis of the jaw, though denosumab presents a somewhat higher risk. The reduced fracture rate from prompt treatment with anti-resorptive therapy likely outweighs the jaw risk. Current guidance emphasizes optimizing dental hygiene to reduce risk and scheduling needed dental extractions in a timely fashion, with no convincing evidence to support drug holidays specifically for dental procedures.23EMJ Rheumatology. An Update on Medication-Related Osteonecrosis of the Jaw in Patients with Osteoporosis A rheumatologist can coordinate with your dentist and help you weigh these risks clearly rather than letting fear of an uncommon side effect keep you from treating a common and serious condition.
Calcium, Vitamin D, and Lifestyle in the Treatment Plan
Medications get most of the attention, but a rheumatologist also ensures the foundation is in place. Adequate calcium and vitamin D intake, whether through diet or supplements, is considered part of the optimal standard of care for osteoporosis. When pharmacologic therapy is prescribed, continued calcium and vitamin D intake is recommended for optimal fracture risk reduction.24PubMed Central. The use of calcium and vitamin D in the management of osteoporosis A rheumatologist will check your vitamin D level, correct it if low, and make sure you are getting enough calcium without overdoing it. They also typically discuss weight-bearing exercise, fall prevention strategies, and sometimes refer to physical therapy, especially after a fracture.
Working Within a Larger Team
Managing compromised bone health often requires a team. Optimal bone health care can involve orthopedic surgeons, primary care physicians, nutritionists, and metabolic bone specialists in endocrinology, rheumatology, or gynecology, all working in a coordinated effort.25PubMed. Team Approach: Bone Health Optimization in Orthopaedic Surgery In practice, this means your rheumatologist may be the person who diagnoses osteoporosis after a fracture, initiates treatment, and then communicates the plan to your primary care doctor for ongoing monitoring. Or a fracture liaison service, which systematically identifies patients who have broken a bone and need osteoporosis evaluation, may route you to rheumatology.
One study at a Southern California county hospital found that only 14% of patients flagged by a fracture liaison service were actually seen in a rheumatology clinic, but the service still improved outcomes because primary care physicians were notified of each patient’s fracture risk. The post-service group saw significantly more patients treated with osteoporosis medications and prescribed calcium and vitamin D after discharge.26ACR Meeting Abstracts. Fracture Liaison Service Outcomes at a Southern California County Hospital Highlights Need for Health System Improvements The rheumatologist does not have to see every patient personally to make a difference; sometimes the biggest contribution is setting up the systems and protocols that catch people who would otherwise fall through the cracks.
When You Might Be Referred to a Rheumatologist Specifically
Not every person with osteoporosis needs a rheumatologist. If you are a postmenopausal woman with straightforward low bone density, no secondary causes, and no complicating conditions, your primary care doctor can often handle diagnosis and treatment just fine. But referral to a rheumatologist makes sense in several situations:
- Glucocorticoid use: If you are on long-term steroids for any reason, a rheumatologist can integrate bone protection into your overall disease management.
- Inflammatory arthritis: RA, psoriatic arthritis, and ankylosing spondylitis all affect bone, and treating the inflammation is part of treating the bone loss.
- Fractures despite treatment: If you break a bone while on osteoporosis medication, a specialist can reassess, check for secondary causes, and consider switching to a different drug class.
- Complex medication decisions: Choosing between anabolic and antiresorptive therapy, sequencing drugs, managing denosumab transitions, or navigating cardiovascular risk with romosozumab all benefit from specialist input.
- Premenopausal osteoporosis: Bone loss in younger women or in men often has an underlying cause that a rheumatologist is trained to investigate.
If you find yourself in one of these situations, a rheumatologist brings a particular kind of value: they understand both the medications and the diseases that drive the bone loss, and they can plan treatment sequences that unfold over years rather than thinking one prescription at a time.